Windlas Biotech Limited
WINDLAS · ISIN: INE0H5O01029
Windlas Biotech Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE0H5O01029.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Windlas Biotech Limited - growth of ₹100
Growth of ₹100 invested on 2021-11-30, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-15.39%
3M
+7.66%
6M
+8.4%
1Y
-0.59%
3Y CAGR
+40.22%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Windlas Biotech Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
No recent block/bulk/short-sell deals on record for this stock.
Frequently asked questions
What is Windlas Biotech Limited's 1-year and 3-year return?
Windlas Biotech Limited's 1-year price return is -0.59%. Its 3-year CAGR (annualized return) is +40.22%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Windlas Biotech Limited's latest financial performance?
Windlas Biotech Limited's trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹942 Cr, with a TTM profit after tax of ₹67 Cr and an EBITDA margin of null%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹31.64, with a 5-year EPS growth rate of 53.86% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Windlas Biotech Limited's quality score?
Windlas Biotech Limited has a Punji quality score of 100 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Windlas Biotech Limited's technical indicators show?
As of 2026-10-29, Windlas Biotech Limited's RSI (14-day) is 42.52 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Windlas Biotech Limited?
As of 2026-06-30, Windlas Biotech Limited's shareholding is split across Promoter (63.31%), Public (36.69%). Promoter holding of 63.31% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Stock data · Not financial advice · Past performance does not indicate future returns